| Primary |
| Choriocarcinoma |
15.0% |
| Gestational Trophoblastic Tumour |
13.1% |
| Rhabdomyosarcoma |
12.6% |
| Germ Cell Cancer |
9.7% |
| Nephroblastoma |
8.7% |
| Benign Hydatidiform Mole |
6.8% |
| Lung Neoplasm |
5.8% |
| Prophylaxis Of Nausea And Vomiting |
5.8% |
| Drug Use For Unknown Indication |
3.9% |
| Malignant Melanoma |
3.4% |
| Primitive Neuroectodermal Tumour |
2.9% |
| Sarcoma Metastatic |
2.4% |
| Ewing's Sarcoma |
1.5% |
| Fibrosarcoma |
1.5% |
| Renal Neoplasm |
1.5% |
| Undifferentiated Sarcoma |
1.5% |
| Astrocytoma |
1.0% |
| Chemotherapy |
1.0% |
| Hypertension |
1.0% |
| Immunosuppressant Drug Therapy |
1.0% |
|
| Venoocclusive Disease |
9.6% |
| Post Procedural Complication |
7.7% |
| Sepsis |
7.7% |
| Vomiting |
7.7% |
| Pyrexia |
5.8% |
| Respiratory Failure |
5.8% |
| Troponin Increased |
5.8% |
| Uterine Haemorrhage |
5.8% |
| Venoocclusive Liver Disease |
5.8% |
| White Blood Cell Count Decreased |
5.8% |
| Anaemia |
3.8% |
| Neutropenic Sepsis |
3.8% |
| Ototoxicity |
3.8% |
| Staphylococcal Infection |
3.8% |
| Staphylococcus Test Positive |
3.8% |
| Tooth Malformation |
3.8% |
| Weight Increased |
3.8% |
| Ascites |
1.9% |
| Blood Potassium Decreased |
1.9% |
| Febrile Bone Marrow Aplasia |
1.9% |
|
| Secondary |
| Rhabdomyosarcoma |
21.2% |
| Sarcoma Metastatic |
12.9% |
| Ewing's Sarcoma |
10.7% |
| Product Used For Unknown Indication |
10.0% |
| Neoplasm Malignant |
9.7% |
| Foetal Exposure During Pregnancy |
7.1% |
| Gestational Trophoblastic Tumour |
4.3% |
| Bone Sarcoma |
4.1% |
| Sarcoma |
3.8% |
| Nephroblastoma |
2.9% |
| Choriocarcinoma |
2.3% |
| Drug Use For Unknown Indication |
2.1% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Ovarian Germ Cell Cancer |
1.6% |
| Germ Cell Cancer |
1.4% |
| Malignant Melanoma |
1.3% |
| Breast Cancer |
0.8% |
| Malignant Melanoma Stage Iii |
0.7% |
| Chemotherapy |
0.5% |
| Metastatic Choriocarcinoma |
0.4% |
|
| Febrile Neutropenia |
13.1% |
| Mucosal Inflammation |
13.1% |
| Thyroid Cancer |
9.0% |
| Febrile Bone Marrow Aplasia |
6.9% |
| Respiratory Failure |
6.9% |
| Epistaxis |
4.8% |
| Off Label Use |
4.8% |
| Treatment Related Secondary Malignancy |
4.5% |
| Ototoxicity |
4.2% |
| Vomiting |
4.2% |
| Premature Baby |
3.5% |
| Weight Decreased |
3.5% |
| Cellulitis |
3.1% |
| Sepsis |
3.1% |
| Candida Test Positive |
2.8% |
| Pyrexia |
2.8% |
| Thrombocytopenia |
2.8% |
| Tachycardia |
2.4% |
| Toxicity To Various Agents |
2.4% |
| Myelitis |
2.1% |
|
| Concomitant |
| Rhabdomyosarcoma |
15.3% |
| Chemotherapy |
14.0% |
| Nuclear Magnetic Resonance Imaging |
10.8% |
| Nephroblastoma |
8.1% |
| Ewing's Sarcoma |
6.8% |
| Metastases To Lung |
6.3% |
| Product Used For Unknown Indication |
4.5% |
| Prophylaxis |
4.5% |
| Choriocarcinoma |
3.6% |
| Malignant Melanoma |
3.2% |
| Febrile Neutropenia |
2.7% |
| Neuroblastoma |
2.7% |
| Testis Cancer |
2.7% |
| B-cell Lymphoma |
2.3% |
| Gestational Trophoblastic Tumour |
2.3% |
| Prophylaxis Of Nausea And Vomiting |
2.3% |
| Sarcoma |
2.3% |
| Teratoma |
2.3% |
| Cord Blood Transplant Therapy |
1.8% |
| Nuclear Magnetic Resonance Imaging Brain |
1.8% |
|
| Thrombocytopenia |
28.3% |
| Drug Toxicity |
8.7% |
| Nephrogenic Systemic Fibrosis |
6.5% |
| Treatment Failure |
6.5% |
| Vomiting |
6.5% |
| Ejection Fraction Decreased |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Intracardiac Thrombus |
4.3% |
| Renal Tubular Disorder |
4.3% |
| Xerosis |
4.3% |
| Agranulocytosis |
2.2% |
| Back Pain |
2.2% |
| Blood Human Chorionic Gonadotropin Increased |
2.2% |
| Blood Pressure Inadequately Controlled |
2.2% |
| Death |
2.2% |
| Drug Hypersensitivity |
2.2% |
| Drug Interaction |
2.2% |
| Encephalopathy |
2.2% |
| Exsanguination |
2.2% |
| Faecal Incontinence |
2.2% |
|
